2Brian C, Yiqing S, Eric L, et al. Circuiting Lev-els of Resistin and Risk of Type 2 Diabetes in Men and Women:Results From Two Prospective Cohorts. Diabetes Care, 2009 ; 32 ( 2 ) : 329 - 334.
7Nikolaos P, Despina P, Fotios I, et al. Exercise Reduces Resistin and Inflammatory Cytokines in Patients With Type 2 Diabetes. Diabetes Care, 2007,30(10) :719 -722.
6Bozaoglu K, Bolton K, MeMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J]. Endocrinology, 2007,148(10) : 4687-4694.
7Trayhum P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ[JJ. Proc Nutr Soc,2001,60(3) :329-339.
8Takahashi M, Takahashia Y, Takahashib K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3Ta-L1 adipoeytes[J]. FEBS Letters, 2008, 582 (5): 573-578.
9Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance[J]. J Clin Invest, 2003,112 (8) : 1821-1830.
10Mori Y, Hoshino K, Yokota K, et al. Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men[J]. Exp Clin Endocrinol Diabetes,2005(6) :113- 113.
3National Cholesterol Education Program ( NCEP) expert panel ondetection,evaluation,and treatment of high blood cholesterol in a-dults( Adult Treatment Panel III) . Third report of the NationalCholesterol Education Program ( NCEP) expert panel on detec-tion ,evaluation,and treatment of high blood cholesterol in adults(Adult Treatment Panel III) final report. Circulation’2002,106(25):3143-3421.
4Steppan CM, Lazar MA. Resistin and obesity-associated insulinresistance. Trends Endocrinol Metab,2002,13( 1 ) :18-23.
5Kim TN,Kim JM,Won JC,et al. A decision tree-based approachfor identifying urban-rural differences in metabolic syndrome riskfactors in the adult Korean population. J Endocrinol Invest,2012,35(9) :847-852.
6Reaven GM. Banting lecture 1988. Role of insulin resistance inhuman disease. Diabetes, 1988,37(12) : 1595-1607.
7Michos ED,Sibley CT’Baer JT’et al. Niacin and statin combina-tion therapy for atherosclerosis regression and prevention of cardi-ovascular disease events : reconciling the AIM-HIGH ( Athero-thrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides:Impact on Global Health Outcomes) trial withprevious surrogate endpoint trials. J Am Coll Cardiol, 2012 , 59(23) :2058-2064.
8Wilson PW,Kannei WB,Silbershatz H,et al. Clustering of meta-bolic factors and coronary heart disease. Arch Intern Med, 1999 ,159(10) :1104-1109.
9Steppan CM,Bailey ST,Bhat S,et al. The hormone resistin linksobesity to diabetes. Nature,2001,409(6818) :307-312.
10Kochan Z, Karbowska J. Resistine—a new hormone secreted byadipose tissue ( adipose tissue in insulin resistance) . Przegl Lek,2003,60(1) ;40^2.
